|
HOUSE OF REPRESENTATIVES |
H.C.R. NO. |
48 |
|
THIRTIETH LEGISLATURE, 2020 |
|
|
|
STATE OF HAWAII |
|
|
|
|
|
|
|
|
||
|
|
||
HOUSE CONCURRENT
RESOLUTION
URGING THE UNITED STATES CONGRESS TO KEEP THE AMERICAN PEOPLE SAFE AND HEALTHY BY DECREASING THE NATION'S DEPENDENCY ON FOREIGN MANUFACTURED PHARMACEUTICAL INGREDIENTS AND MEDICINE, PARTICULARLY FROM CHINA
WHEREAS, millions of Americans depend on
pharmaceutical drugs to cure, treat, or prevent disease and these drugs can
result in lifesaving and life sustaining outcomes; and
WHEREAS, China has become the world’s
largest supplier of active pharmaceutical ingredients and the U.S. Food and
Drug Administration estimates that at least eighty per cent of active
pharmaceutical ingredients are manufactured outside of the United States, mainly
in China; and
WHEREAS, China's dominance in supplying the
United States' chemical and pharmaceutical sector has driven out many U.S.
based pharmaceutical companies resulting in a loss of capacity to domestically
produce vital drugs used by patients every day; and
WHEREAS, the increased dependence on
Chinese produced active pharmaceutical ingredients creates a national security
risk and public health risk that cannot be overstated, as it results in U.S.
dependence on foreign-sourced pharmaceuticals; and
WHEREAS, due to America's dependence on
Chinese produced active pharmaceutical ingredients, China could weaponize its
position in the pharmaceutical supply chain to the disadvantage and peril of
the citizens of the United States by manipulating or cutting off the supply of
active pharmaceutical ingredients; now, therefore,
BE
IT RESOLVED by the House of Representatives of the Thirtieth Legislature of the
State of Hawaii, Regular Session of 2020, the Senate concurring, the U.S. Congress
is urged to decrease the nation's dependence on foreign manufactured medicines,
particularly from China to ensure the continuity and safety of the supply of
the products and keep the American people safe and healthy; and
BE IT FURTHER RESOLVED that the U.S. Congress
is advised to develop a white paper on the methods, materials, and timeline
necessary to phase out or reduce American dependence on the manufacture of active
pharmaceutical ingredients by potentially hostile powers, such as China and
Russia; and
BE IT FURTHER RESOLVED that the U.S.
Congress is urged to incentivize the
creation or reestablishment of American owned and operated active
pharmaceutical ingredients factories in the United States; and
BE IT FURTHER RESOLVED that certified copies
of this Resolution be transmitted to the President of the United States, the
Vice President of the United States, the Speaker of the United States House of
Representatives, the Minority Leader of the United States House of
Representatives, the President of the United States Senate, the Secretary of
Defense, the Secretary of State, the Office of the Surgeon General, the Centers
for Disease Control, the U.S. Department of Health and Human Services, the
Joint Chiefs Of Staff, Blue Cross Blue Shield Association, Kaiser Permanente,
Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck & Co, AbbVie Inc,
Bristol-Myers Squibb, Eli Lilly and Company, Biogen, Abbott Laboratories,
Stryker Corporation, and Regeneron.
|
|
OFFERED BY: |
_____________________________ |
|
|
|
|
Urging the U.S. Government to Decrease Dependency on Foreign Pharmaceuticals